Volume 21 Supplement 1
Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium
Proceedings
Publication of this supplement has been supported by the SJIA Foundation. The articles have undergone the journal's standard peer review process for supplements.
Virtual16-18 February 2022
-
Citation: Pediatric Rheumatology 2024 21(Suppl 1):91
-
The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still’s disease
Currently, the criteria used to classify patients with SJIA are different from those used for AOSD. However, it has been recognized that the existing terms are too narrow, subdividing the Still’s population un...
Citation: Pediatric Rheumatology 2024 21(Suppl 1):114 -
The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA
Although the introduction of the IL-1 and IL-6 inhibiting biologics in 2012 has revolutionized the treatment and markedly improved outcomes for many patients with SJIA, about 20% of these patients continue to ...
Citation: Pediatric Rheumatology 2024 21(Suppl 1):87 -
The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study
The substantial morbidity and mortality associated with refractory systemic JIA underlies the need for new treatment approaches. However, progress in this area has been limited by the difficulty of enrolling t...
Citation: Pediatric Rheumatology 2024 21(Suppl 1):150 -
The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?
Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, the...
Citation: Pediatric Rheumatology 2024 21(Suppl 1):79 -
Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe
It has been increasingly recognized that there is a subset of patients with refractory systemic JIA, who have failed all available medications and may benefit from HSCT. The increasing experience with HSCT in ...
Citation: Pediatric Rheumatology 2024 21(Suppl 1):86
Official journal of
Annual Journal Metrics
-
2022 Citation Impact
2.5 - 2-year Impact Factor
3.0 - 5-year Impact Factor
1.035 - SNIP (Source Normalized Impact per Paper)
0.732 - SJR (SCImago Journal Rank)2023 Speed
18 days submission to first editorial decision for all manuscripts (Median)
94 days submission to accept (Median)2023 Usage
1,095,144 downloads
691 Altmetric mentions